FDA To Complete 510(k) Review Before Addressing Off-Label Use Concerns
This article was originally published in The Gray Sheet
Review of a 510(k) must continue to completion prior to addressing any concerns regarding off-label use of the device, FDA instructs Office of Device Evaluation staff in its recent "Determination of Intended Use for 510(k) Devices" guidance.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.